Summit Therapeutics and AstraZeneca are discussing a partnership deal worth as much as $15 billion, Bloomberg News reported ...

AstraZeneca Plc is discussing a partnership deal with Summit Therapeutics Inc. in which it could pay as much as $15 billion ...

Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...

AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...

The biopharmaceutical giant AstraZeneca is considering moving their stock listing from the London Stock Exchange to the US in ...

AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s ...

Summit Therapeutics (NASDAQ:SMMT) stock rose 5% on Thursday while AstraZeneca (NASDAQ:AZN) shares fell 2% following a Bloomberg report that the companies are in discussions for a potential $15 billion ...

AstraZeneca is reportedly considering moving its listing to the US. Here's why AZN's expected departure is alarming for the ...

London marked the slowest first half-year for IPO volume since 1997, a grim milestone punctuated by a report that AstraZeneca ...

AstraZeneca PLC closed 23.78% short of its 52-week high of £133.88, which the company achieved on September 3rd.

Spain is investigating Novo Nordisk over concerns it may be illegally advertising its weight loss drugs Ozempic and Wegovy ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...